B-cell receptor specific for tetanus toxoid, diphtheria toxoid, and acellular pertussis antigens (TDaP-specific BCR)

B-cell receptors (BCRs) specific for tetanus toxoid, diphtheria toxoid, and acellular pertussis antigens are specialized membrane-bound immunoglobulins expressed on the surface of B lymphocytes. These receptors are responsible for the initial recognition of antigens provided by TDaP or DTaP vaccines, which include inactivated toxins from Clostridium tetani and Corynebacterium diphtheriae, as well as purified components of Bordetella pertussis (CDC, 2020). Upon antigen binding, the BCR complex initiates a signal transduction cascade that leads to B-cell activation, proliferation, and differentiation into long-lived memory B cells and antibody-secreting plasma cells (Janeway et al., 2001). This process is fundamental to the development of protective immunity, as the resulting antibodies neutralize the toxins and bacteria upon subsequent exposure. The efficacy of vaccination is typically measured by the induction of high-affinity antibodies produced by these activated B-cell lineages (Pollard & Bijker, 2021). However, the use of these antigens can occasionally lead to hypersensitivity reactions or other adverse effects, particularly in individuals with high pre-existing antibody titers (Siegrist, 2018). Overall, these specific BCRs are the primary cellular targets for achieving active immunization against these three significant infectious diseases.

Other names

Tetanus-specific B-cell receptorDiphtheria-specific B-cell receptorPertussis-specific B-cell receptorAnti-TDaP BCRAntigen-specific B-cell receptor

The mechanism involves the binding of vaccine-derived antigens (tetanus toxoid, diphtheria toxoid, and acellular pertussis components) to the membrane-bound immunoglobulin of the B-cell receptor. This binding triggers receptor clustering and activation of the Ig-alpha/Ig-beta (CD79a/CD79b) signaling complex, leading to downstream phosphorylation events, B-cell activation, and the eventual production of high-affinity IgG antibodies and memory B cells (Janeway et al., 2001; Pollard & Bijker, 2021).